Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

Chien An Chen, Chun Ju Chiang, Yun Yuan Chen, San Lin You, Shu Feng Hsieh, Chao Hsiun Tang, Wen Fang Cheng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

Original languageEnglish
Article numbere16
JournalJournal of Gynecologic Oncology
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Keywords

  • Disease-Free Survival
  • Drug Therapy
  • Ovarian Neoplasms
  • Survival
  • Taxane

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens'. Together they form a unique fingerprint.

  • Cite this